Mayo and LipoScience in Collaboration

A collaborative agreement between Mayo Clinic's Department of Laboratory Medicine and Pathology (Rochester, MN, USA) and LipoSciences (Raleigh, NC, USA) has been announced, whereby the Mayo Clinic will validate the clinical utility of the nuclear magnetic resonance (NMR) LipoProfile test of LipoSciences as a tool to measure cardiovascular risks.

As part of its assessment, Mayo researchers will determine the value of the NMR LipoProfile test independently and as part of its novel cardiovascular risk marker panel, a group of emerging risk factors used to aid doctors in the assessments of their patients' risks for developing cardiovascular disease or experiencing a cardiovascular event such as a stroke.

The NMR LipoProfile is a simple blood test used by doctors to directly measure the number of atherogenic low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) particles as well as protective high-density lipoprotein (HDL) particles. Measuring the numbers of "bad” lipoprotein particles (LDL-P) has been found to provide a better indication of the risk of coronary heart disease than measuring the level of "bad” cholesterol.

"Mayo Clinic is widely recognized as a leader in assessing novel technologies that have the potential to significantly impact medical decisions and patient management,” explained Richard O. Brajer, president and chief executive officer at LipoScience, Inc. "We believe a preeminent institution such as Mayo Clinic will generate additional independent clinical data further confirming the clinical value of the NMR LipoProfile test.”




Related Links:
Mayo Medical Laboratories
LipoScience